`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`IN RE: OZEMPIC
`(SEMAGLUTIDE) PATENT
`LITIGATION
`
`MDL No. 22-MD-3038-CFC
`
`ANDA CASE
`
`NOVO NORDISK INC. and NOVO
`NORDISKA/S,
`
`Plaintiffs,
`
`V.
`
`C.A. No. 22-1040-CFC
`
`ANDA CASE
`
`MYLAN PHARMACEUTICALS
`INC.,
`
`Defendant.
`
`STIPULATION AND (PROPOSE~RDER
`REGARDING TRIAL OF THE MPI OZEMPIC LITIGATION
`
`WHEREAS, on March 18, 2022, Novo Nordisk Inc. and Novo Nordisk A/S
`
`("Plaintiffs") sued Mylan Pharmaceuticals Inc. ("MPI") in the United States District
`
`Court for the No1ihern District of West Virginia in a case captioned Novo Nordisk
`
`Inc. and Novo Nordisk AIS v. Mylan Pharmaceuticals Inc., No. 1:22-cv-23-JPB
`
`(N.D.W. Va.) ("MPI Ozempic Litigation"), D.I. l;
`
`WHEREAS, the MPI Ozempic Litigation is currently pending in the District
`
`of Delaware as Case No. 22-1040 (CFC) because, on August 5, 2022, the United
`
`States Judicial Panel on Multidistrict Litigation transfen-ed the MPI Ozempic
`
`Litigation to the United States District Court for the District of Delaware "for
`
`1
`
`Novo Nordisk Exhibit 2004
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00001
`
`
`
`Case 1:22-cv-01040-CFC Document 162 Filed 10/31/23 Page 2 of 4 PageID #: 4349
`
`coordinated or consolidated pretrial proceedings." In re Ozempic (Semaglutide)
`
`Patent Litigation, MDL No. 3038 (J.P.M.L.), D.I. 1;
`
`WHEREAS on March 21, 2023, Plaintiffs filed a First Amended Complaint
`
`against MPI in the MPI Ozempic Litigation (In re: Ozempic (Semaglutide) Patent
`
`Litigation, No. 22-md-3038 (D. Del.), D.I. 111);
`
`WHEREAS, for purposes of this case only, MPI will not dispute that the
`
`District of Delaware has personal jurisdiction and subject matter jurisdiction over
`
`the claims and counterclaims asserted in the MPI Ozempic Litigation under§§ 1331,
`
`1338(a), 2201, and/or 2202;
`
`WHEREAS, for purposes of this case only, MPI will not dispute that venue
`
`is proper in the District of Delaware;
`
`WHEREAS, based on the unique facts of this case, Plaintiffs and MPI agree
`
`all claims and counterclaims between them should remain in the District of Delaware
`
`for trial;
`
`WHEREAS, for purposes of this case only, MPI waives its ability to seek a
`
`remand of the MPI Ozempic Litigation to the Northern District of West Virginia
`
`following the conclusion of coordinated pretrial proceedings in In re Ozempic
`
`(Semaglutide) Patent Litigation, MDL No. 3038 (J.P.M.L.) and agrees that the MPI
`
`Ozempic Litigation shall remain in the District of Delaware for trial as part of In re
`
`Ozempic (Semaglutide) Patent Litigation, MDL No. 22-MD-3038 (CFC).
`
`2
`
`Novo Nordisk Exhibit 2004
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00002
`
`
`
`Case 1:22-cv-01040-CFC Document 162 Filed 10/31/23 Page 3 of 4 PageID #: 4350
`
`IT IS HEREBY STIPULATED, subject to the approval of the Court, that
`
`Plaintiffs and MPI will remain in the District of Delaware for trial of all claims and
`
`counterclaims raised in In re Ozempic (Semaglutide) Patent Litigation, MDL No.
`
`3038 (J.P.M.L.) and in the MPI Ozempic Litigation, which was originally filed as
`
`Novo Nordisk Inc. and Novo Nordisk AIS v. Mylan Pharmaceuticals Inc., No. 1 :22-
`
`cv-23-JPB (N.D.W. Va.), and is presently pending as Case No. 22-1040 (CFC) (D.
`
`Del.). All such claims and counterclaims shall be tried as part of the trial presently
`
`scheduled to begin in Delaware on September 30, 2024 in In re Ozempic
`
`(Semaglutide) Patent Litigation, MDL No. 22-MD-3038 (CFC), which includes the
`
`consolidated cases pending under Lead Case No. 22-294 (CFC) and the MPI
`
`Ozempic Litigation.
`
`MORRIS,NICHOLS,ARsHf &TuNNELLLLP
`
`STAMOULIS & WEINBLA TT LLC
`
`/s/ <Travis J. :M.urray
`
`/s/ Stamatios Stamou{is
`
`Stamatios Stamoulis ( #4606)
`Richard C. Weinblatt (#5080)
`800 North West Street, 3rd Floor
`Wilmington, DE 19801
`(302) 999-1540
`stamoulis@swdelaw.com
`weinblatt@swdelaw.com
`
`Attorneys for Defendant
`Mylan Pharmaceuticals Inc.
`
`Jack B. Blumenfeld (#1014)
`Brian P. Egan (#6227)
`Travis J. Murray (#6882)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`began@morrisnichols.com
`tmurray@morrisnichols.com
`
`Attorneys for Plaintiffs Novo Nordisk
`Inc. and Novo Nordisk AIS
`
`3
`
`Novo Nordisk Exhibit 2004
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00003
`
`
`
`Case 1:22-cv-01040-CFC Document 162 Filed 10/31/23 Page 4 of 4 PageID #: 4351
`
`SO ORDERED this Ji✓r day of Q c;f.Lv
`
`, 2023.
`
`The Honorable Cohn F. Connolly
`Chief, United States District Judge
`
`4
`
`Novo Nordisk Exhibit 2004
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00004
`
`